Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lung cancer

H H Hansen1, M Rørth

  • 1Department of Oncology 5074, Finsen Institute Rigshospitalet, Copenhagen, Denmark.

Cancer Chemotherapy and Biological Response Modifiers
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Combination chemotherapy is the main treatment for small cell lung cancer, yielding high response rates. Granulocyte-colony stimulating factor (G-CSF) reduces side effects without impacting survival outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of alternative feed additives to medicinal zinc oxide on productivity, diarrhoea incidence and gut development in weaned piglets.

Animal : an international journal of animal bioscience·2020
Same author

Evaluation of the feeding value of Dichrostachys cinerea pods for fattening pigs in Cuba.

Tropical animal health and production·2017
Same author

High plasma triglyceride levels strongly correlate with low kisspeptin in the arcuate nucleus of male rats.

Endocrine regulations·2015
Same author

Technical note: In vitro total gas and methane production measurements from closed or vented rumen batch culture systems.

Journal of dairy science·2014
Same author

Neurotoxic effects of MDMA (ecstasy) on the developing rodent brain.

Developmental neuroscience·2010
Same author

The medullary nail presentation of a new type and report of a case.

Archives of surgery (Chicago, Ill. : 1920)·2010
Same journal

Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Human tumor associated antigen mimicry by xenoantigens, anti-idiotypic antibodies and peptide mimics: implications for immunotherapy of malignant diseases.

Cancer chemotherapy and biological response modifiers·2005
Same journal

DNA vaccines for melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Immunizing against partially defined antigen mixtures, gangliosides, or peptides to induce antibody, T cell, and clinical responses.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Chemotherapy, cytokines, and biochemotherapy for melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Current status of interferon-alpha in the treatment of melanoma.

Cancer chemotherapy and biological response modifiers·2005
See all related articles

Area of Science:

  • Oncology
  • Medical Chemotherapy

Background:

  • Small cell lung cancer (SCLC) treatment relies heavily on combination chemotherapy.
  • Etoposide dose scheduling and continuous treatment duration are crucial factors.

Purpose of the Study:

  • To review current combination chemotherapy regimens for SCLC.
  • To assess the impact of G-CSF on chemotherapy side effects and outcomes.
  • To evaluate treatment strategies for non-SCLC.

Main Methods:

  • Review of existing studies on SCLC combination chemotherapy.
  • Analysis of G-CSF use alongside chemotherapy in SCLC patients.
  • Examination of treatment outcomes for non-SCLC types.

Main Results:

  • Combination chemotherapy achieves 80-90% response rates in SCLC, with median survival of 11-16 months.

Related Experiment Videos

  • G-CSF reduces neutropenia, fever, and hospitalization but does not alter response rates or survival.
  • Standard chemotherapy is not established for non-SCLC, with experimental results for induction chemotherapy and radiotherapy.

    • Conclusions:

    • Combination chemotherapy remains the cornerstone for SCLC, with ongoing research into optimal treatment duration.
    • G-CSF can mitigate chemotherapy toxicity in SCLC patients.
    • Further advancements in systemic and local treatments are necessary for non-SCLC.